Unknown

Dataset Information

0

Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Immune Dysregulatory Disorders.


ABSTRACT: Primary immunodeficiency disorders that predominantly affect immune regulation and mechanisms of self-tolerance have come into the limelight, because at least for a subgroup of monogenetic disorders, a targeted therapy has become available. Nevertheless, their management often involves the treatment of severely compromising, refractory, multi-organ autoimmunity, leading to further increased susceptibility to infections and complications of long-term immune suppressive treatment, including the risk of malignancy. While evidence for allogeneic hematopoietic stem cell transplantation (alloHSCT) as a curative treatment option for severely affected patients by this disease category accumulates, clear indications, and guidelines for alloHSCT are lacking. Predictive and stratification-relevant tools such as disease activity scores are largely missing and often there is not a consistent genotype-phenotype correlation within the same family to facilitate the decision whether to transplant or not. In this review, we provide a literature-based update on indications and outcomes of alloHSCT for congenital immune dysregulative inborn errors of immunity according to the IUIS classification 2017.

SUBMITTER: Bakhtiar S 

PROVIDER: S-EPMC6865355 | BioStudies | 2019-01-01

SECONDARY ACCESSION(S): 102582

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6821686 | BioStudies
2019-01-01 | S-EPMC6816315 | BioStudies
2017-01-01 | S-EPMC5281554 | BioStudies
2020-01-01 | S-EPMC7225316 | BioStudies
2018-01-01 | S-EPMC5742601 | BioStudies
2018-01-01 | S-EPMC6173278 | BioStudies
2020-01-01 | S-EPMC7082388 | BioStudies
2019-01-01 | S-EPMC6718615 | BioStudies
2018-01-01 | S-EPMC5948470 | BioStudies
2020-01-01 | S-EPMC7314950 | BioStudies